Articles

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia
Division of Hematology/Oncology, Columbia University, New York, NY, USA
Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, Tübingen, Germany
Unite de Genomique du Myelome, CHU Rangueil, Toulouse, France
Department of Medicine, University of Colorado, Aurora, CO, USA
Clinical Department of Haematology, 1st Medical Department, Charles University in Prague, Czech Republic
Department of Haematology and Stem Cell Transplantation, St László Hospital, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Department of Hematology, Sunderbyn Hospital, Luleå, Sweden
Albert Schweitzer Hospital Department of Internal Medicine, Dordrecht, the Netherlands
Department of Hematology, Careggi Hospital and University of Florence, Italy
Irmandade Da Santa Casa De Misericordia De São Paulo, Brazil
“Seràgnoli” Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea
Winship Cancer Institute, Emory University, Atlanta, GA, USA
St. Vincent’s Hospital, University of Melbourne, Australia
Royal Adelaide Hospital, North Terrace, Australia
Hospital Santa Marcelina, São Paulo, Brazil
Fondazione IRCCS Instituto Nazionale dei Tumori, University of Milan, Italy
Seoul St. Mary’s Hospital, South Korea
Oregon Health & Science University, Portland, OR, USA
Mayo Clinic Florida, Jacksonville, FL, USA;
Royal Adelaide Hospital, North Terrace, Australia
Instituto do Cancer-Hospital Mae de Deus, Porto Alegre, Brazil
Ankara University, Turkey
Hospital Angeles Lomas, Naucalpan de Juárez y alrededores, México
Ulsan University Hospital, South Korea
Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, South Korea
Erasmus Medical Center, Rotterdam, the Netherlands
Janssen Research & Development, LLC, Spring House, PA, USA
Janssen Research & Development, Beerse, Belgium
Janssen Research & Development, LLC, Spring House, PA, USA
Janssen Research & Development, LLC, Raritan, NJ, USA
Janssen Research & Development, LLC, Spring House, PA, USA
Janssen Research & Development, High Wycombe, UK
Genmab US, Inc, Princeton, NJ, USA
Janssen Research & Development, LLC, Raritan, NJ, USA
University Hospital of Salamanca/IBSAL, Spain
Vol. 103 No. 12 (2018): December, 2018 https://doi.org/10.3324/haematol.2018.194118